Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant

( views:85, downloads:0 )
Author:
YANG Yang(Liver Transplant Center, Third Affiliated Hospital of Sun Yat-sen University, Transplantation Research Institute of Sun Yat-sen University, Guangzhou 510630, China)
WANG Gen-shu(Liver Transplant Center, Third Affiliated Hospital of Sun Yat-sen University, Transplantation Research Institute of Sun Yat-sen University, Guangzhou 510630, China)
YI Shu-hong(Liver Transplant Center, Third Affiliated Hospital of Sun Yat-sen University, Transplantation Research Institute of Sun Yat-sen University, Guangzhou 510630, China)
ZHANG Jian(Liver Transplant Center, Third Affiliated Hospital of Sun Yat-sen University, Transplantation Research Institute of Sun Yat-sen University, Guangzhou 510630, China)
ZHANG Jun-feng(Liver Transplant Center, Third Affiliated Hospital of Sun Yat-sen University, Transplantation Research Institute of Sun Yat-sen University, Guangzhou 510630, China)
YI Hui-min(Liver Transplant Center, Third Affiliated Hospital of Sun Yat-sen University, Transplantation Research Institute of Sun Yat-sen University, Guangzhou 510630, China)
ZHANG Ying-cai(Liver Transplant Center, Third Affiliated Hospital of Sun Yat-sen University, Transplantation Research Institute of Sun Yat-sen University, Guangzhou 510630, China)
CHEN Gui-hua(Liver Transplant Center, Third Affiliated Hospital of Sun Yat-sen University, Transplantation Research Institute of Sun Yat-sen University, Guangzhou 510630, China)
ZHANG Qi(Liver Transplant Center, Third Affiliated Hospital of Sun Yat-sen University, Transplantation Research Institute of Sun Yat-sen University, Guangzhou 510630, China)
CAI Chang-jie(Liver Transplant Center, Third Affiliated Hospital of Sun Yat-sen University, Transplantation Research Institute of Sun Yat-sen University, Guangzhou 510630, China)
LU Ming-qiang(Liver Transplant Center, Third Affiliated Hospital of Sun Yat-sen University, Transplantation Research Institute of Sun Yat-sen University, Guangzhou 510630, China)
LI Xi(Liver Transplant Center, Third Affiliated Hospital of Sun Yat-sen University, Transplantation Research Institute of Sun Yat-sen University, Guangzhou 510630, China)
JIANG Nan(Liver Transplant Center, Third Affiliated Hospital of Sun Yat-sen University, Transplantation Research Institute of Sun Yat-sen University, Guangzhou 510630, China)
JIANG Hua(Liver Transplant Center, Third Affiliated Hospital of Sun Yat-sen University, Transplantation Research Institute of Sun Yat-sen University, Guangzhou 510630, China)
XU Chi(Liver Transplant Center, Third Affiliated Hospital of Sun Yat-sen University, Transplantation Research Institute of Sun Yat-sen University, Guangzhou 510630, China)
LI Hua(Liver Transplant Center, Third Affiliated Hospital of Sun Yat-sen University, Transplantation Research Institute of Sun Yat-sen University, Guangzhou 510630, China)
Journal Title:
CHINESE MEDICAL JOURNAL
Issue:
Volume 120, Issue 16, 2007
DOI:
Key Word:
liver transplantation; adefovir dipivoxil; YMDD mutant; HBV recurrence

Abstract: Background The most frequently used therapy for post-transplantation recurrence of hepatitis B virus (HBV) infection is lamivudine, but this drug is associated with a high resistance rate due to YMDD mutant. In preliminary reports, adefovir dipivoxil (ADV) has been shown to have activity against lamivudine-resistant strains of HBV. However, clinical experience in treatment of HBV infection after liver transplantation (LT) is still not entirely clear. This study was aimed to evaluate the prophylactic efficacy of ADV plus hepatitis B immunoglobulin (HBIG) in patients with YMDD mutant before LT.Methods From March 2004 to March 2006, 16 patients with chronic hepatitis B had lamivudine-resistant YMDD mutants detected prior to liver transplantation and received treatment with ADV plus additional intramuscular HBIG after LT as prophylaxis against graft reinfection. Tests for liver function, serum HBsAg, anti-HBs (HBIG), HBeAg, anti-HBc,anti-HBe, HBV-DNA, and creatinine were assessed pre- or post-liver transplantation.Results The median follow-up of these patients post-liver transplantation was 19.4 months. Fifteen patients survived and one patient died of recurrence of hepatocellular carcinoma (HCC). There was significant difference (10.98% vs. 2.26%, P<0.05) in YMDD mutant rate between the patients with HBV-DNA over 106 copies/ml and those with HBV-DNA less than 106 copies/ml. Fifteen patients (93.8%) had undetectable HBV-DNA at 4 weeks and 1 (6.3%) at 6 months after LT. No hepatitis B recurrence was detected by persistent testing of HBsAg, HBeAg, and HBV-DNA and no increase of serum creatinine level associated with ADV was observed in any of the patients.Conclusion ADV combined with intramuscular HBIG can effectively prevent patients with pre-transplantation YMDD mutant from HBV recurrence after LT.

  • [1]Wiegand J,Tischendorf JJ,Nashan B,Klempnauer J,Flemming P,Niemann P,et al.Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient:immediate switch to adefovir dipivoxil appears to be indicated.Z Gastroenterol 2004; 42:15-18.
  • [2]Zheng SS,Wu J,Liang TB,Wang WL,Huang DS,Ma WH.Prevention and treatment of hepatitis B virus reinfection following liver transplantation.Chin J Organ Transplant (Chin) 2000; 21:366-368.
  • [3]Liaw YF.Results of lamivudine trials in Asia.J Hepatol 2003;39 (Suppl 1):S111-S115.
  • [4]The Lamivudine Clinical Practice Group.Lamivudine treatment consensus from relative experts.Chin J Hepatol (Chin) 2002; 10:157-158.
  • [5]Stuyver LJ,Locarnini SA,Lok A.Nomenclature for antiviral-resistant human hepatitis B virus mutation in the polymerase region.Hepatology 2001; 33:751-757.
  • [6]Nafa S,Ahmed S,Tavan D,Pichoud C,Berby F,Stuyver L,et al.Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.Hepatology 2000; 32:1078-1088.
  • [7]Westland CE,Yang H,Delaney WE 4th,Wulfsohn M,Lama N,Gibbs CS,et al.Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients.J Viral Hepatol 2005; 12:67-73.
  • [8]Peters MG,Hann Hw H,Martin P,Heathcote EJ,Buggisch P,Rubin R,et al.Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.Gastroenterology 2004; 126:91-101.
  • [9]Ben-Ari Z,Daudi N,Klein A,Sulkes J,Papo O,Mor E,et al.Genotypic and phenotypic resistance:longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation.Am J Gastroenterol 2003; 98:151-159.
  • [10]Qi X,Snow A,Thibault V,Curtis M,Hadziyannis SJ,Brosgart CL,et al.Long-term incidence of adefovir dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy.J Hepatol 2004; 40 (suppl 1):20-21.
  • [11]Han SH,Martin P,Edelstein M,Hu R,Kunder G,Holt C,et al.Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation.Liver Transpl 2003; 9:182-187.
  • [12]Lo CM,Liu CL,Lau GK,Chan SC,Ng IO,Fan ST.Liver transplantation for chronic hepatitis B with lamivudineresistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine.Liver Transpl 2005; 11:807-813.
  • [13]Schiff E,Lai CL,Hadziyannis S,Neuhaus P,Terrault N,Colombo M,et al.Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B:final long-term results.Liver Transpl 2007; 13:349-360.
  • [14]Schiff ER,Lai CL,Hadziyannis S,Neuhaus P,Terrault N,Colombo M,et al.Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre-and post-liver transplantation patients.Hepatology 2003; 38:1419-1427.
  • [15]Zeng MD,Mao YM,Yao GB,Zou XQ,Wang H,Xu DZ,et al.Adefovir dipivoxil for the treatment of hepatitis B antigen-positive chronic hepatitis B in China.Chin J Infect Dis (Chin) 2005; 23:387-394.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn